| Literature DB >> 17885950 |
Matthaios Speletas1, Timoleon-Achilleas Vyzantiadis, Fani Kalala, Dimitrios Plastiras, Kyriaki Kokoviadou, Antonios Antoniadis, Ioannis Korantzis.
Abstract
In this report we describe a patient suffering from chronic myeloid leukemia (CML), who was treated for 4.5 years with imatinib and developed pneumonia caused by two Candida species, i.e., C. krusei and C. glabrata. The patient was in complete hematologic remission and molecular analyses did not display the presence of TLR2-R752Q, TLR4-D299G and TLR4-T399I polymorphisms that may predispose individuals to fungal infections. This case report indicates that in some patients, as previously observed, the long-term administration of targeted therapy might affect immunity and predispose patients to opportunistic and life-threatening fungal infections.Entities:
Mesh：
Substances：
Year: 2008 PMID： 17885950 DOI： 10.1080/13693780701558969
Source DB: PubMed Journal: Med Mycol ISSN： 1369-3786 Impact factor: 4.076